We are on a mission tooutsmart cancer resistance.
Theseus is developing next-generation tyrosine kinase inhibitors (TKIs) to transform the way cancer is treated.
Our targeted, small molecule therapies are designed to address treatment-resistance in cancer.
Working to deliver best-in-class pan-variant tyrosine kinase inhibitors to cancer patients.
We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in clinically significant tyrosine kinase targets.
View our latest news.
Aug 10, 2023
We are building a community working to outsmart cancer resistance. Join us!
SEE OPEN ROLES